TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
Journal of Clinical Oncology · 20.11.2025 · 43 (33) · 3578-3588
DOI: 10.1200/jco-25-01651 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2025. Verfasst von Siamak Daneshmand und 23 weiteren Autor:innen. Beteiligte Einrichtung: University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE TAR-200 is a first-in-class intravesical drug-releasing system designed to provide sustained delivery of gemcitabine in the bladder. TAR-200 alone or in combination with cetrelimab (PD-1 inhibitor) could improve outcomes in patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC) ineligible for or refusing radical cystectomy. METHODS In this phase IIb parallel cohort study, patients with BCG-unresponsive carcinoma in situ (CIS) with/without papillary disease received TAR-200 monotherapy (Cohort 2 [C2]), TAR-200 plus cetrelimab (C1), or cetrelimab monotherapy (C3). Patients with BCG-unresponsive high-risk papillary disease–only NMIBC received TAR-200 monotherapy (C4). TAR-200 was dosed through month 24 and cetrelimab through month 18. Primary end points were centrally confirmed overall complete response (CR) rate (C1-3) or disease-free survival (DFS) rate (C4) (ClinicalTrials.gov number: NCT04640623 ). RESULTS At data cutoff (March 31, 2025), 53, 85, 28, and 52 patients were treated in C1-4, respectively. In C2, CR rate and median duration of response were 82.4% (95% CI, 72.6 to 89.8) and 25.8 months (95% CI, 8.3 to not estimable), respectively. In C4, 6-, 9-, and 12-month DFS rates were 85.3% (95% CI, 71.6 to 92.7), 81.1% (95% CI, 66.7 to 89.7), and 70.2% (95% CI, 51.6 to 82.8), respectively. In C1 and C3, CR rates were 67.9% (95% CI, 53.7 to 80.1) and 46.4% (95% CI, 27.5 to 66.1), respectively. Rates of grade ≥3 treatment-related adverse events (AEs) were 12.9%, 13.5%, 37.7%, and 7.1% in C2, C4, C1, and C3, respectively, and of serious treatment-related AEs, 5.9%, 5.8%, 15.1%, and 3.6%. No treatment-related deaths occurred. CONCLUSION TAR-200 monotherapy was well tolerated, with a high CR rate, durable responses, and prolonged DFS in patients with BCG-unresponsive high-risk NMIBC. TAR-200 monotherapy offered a more favorable risk-benefit profile versus TAR-200 plus cetrelimab or cetrelimab alone in BCG-unresponsive CIS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
- Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Upstate Medical University, Syracuse, NY.
- Hospital Universitario 12 de Octubre, Madrid, Spain.
- Münster University Hospital, Münster, Germany.
- West German Cancer Center, Münster, Germany.
ORCID-Profile: Siamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, Felix Guerrero-Ramos, Christopher M Pieczonka, Nelson Canales Casco, Katie S Murray, Takashi Kawahara, Hussein Sweiti, Andrea Necchi
Zitieren
APA
Daneshmand, S., Van der Heijden, M. S., Jacob, J. M., Guerrero-Ramos, F., Bögemann, M., Simone, G., Pieczonka, C. M., Casco, N. C., Zainfeld, D., Spiegelhalder, P., Xylinas, E., Cahn, D., Lotan, Y., Murray, K. S., Kawahara, T., Stromberg, K., Martin, J., Shukla, A., Cutie, C. J., …, & SunRISe-1 Study (2025). TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. Journal of Clinical Oncology, 43(33), 3578-3588. https://doi.org/10.1200/jco-25-01651
Vancouver
Daneshmand S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, Bögemann M, Simone G, et al. TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. Journal of Clinical Oncology. 2025;43(33):3578-3588. doi:10.1200/jco-25-01651
BibTeX
@article{Daneshmand2025,
author = {Daneshmand, Siamak and Van der Heijden, Michiel S and Jacob, Joseph M and Guerrero-Ramos, Felix and Bögemann, Martin and Simone, Giuseppe and Pieczonka, Christopher M and Casco, Nelson Canales and Zainfeld, Daniel and Spiegelhalder, Philipp and Xylinas, Evanguelos and Cahn, David and Lotan, Yair and Murray, Katie S and Kawahara, Takashi and Stromberg, Katharine and Martin, Jason and Shukla, Abhijit and Cutie, Christopher J and Bertzos, Kristi and Hampras, Shalaka and Sweiti, Hussein and Necchi, Andrea and SunRISe-1 Study, SunRISe-1 Study},
title = {TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {33},
pages = {3578--3588},
doi = {10.1200/jco-25-01651}
}
EUVIMED